Substance use evaluation for private and fiduciary contexts — Minnesota
In some situations, how an evaluation is conducted matters as much as what it finds. When confidentiality, independence, and the absence of any insurance record are essential to the decision at hand, the way this practice is built is part of what makes the evaluation usable. These situations include trust administration and fiduciary distribution decisions, family enterprise and succession questions, professional and reputational matters, anticipated regulatory or employer disclosures, and private clinical questions for which a structured independent reference is wanted.
Arlucent provides confidential, independent substance use evaluation for individuals and for fiduciary, advisory, and counsel-mediated engagements. Evaluations are conducted by secure telehealth and follow the ASAM Criteria, Minnesota’s DHS 245G standards, and DSM-5 and ICD-10 diagnostic conventions. The practice is assessment-only: no treatment, no therapy, no insurance, no claims data, and no continuing clinical relationship. The evaluator’s role concludes with delivery of the written report.
Four operational features define the practice and the scope within which it engages.
The practice does not accept insurance, bill third-party payors, generate claims data, or submit utilization review documentation. That means no record of the engagement in insurance medical history, in the claims databases underwriters query, or in payor-side data reachable by subpoena to an insurer. The clinical record sits within the practice’s own documentation system under standard professional confidentiality, and no part of it goes to a third party without written authorization.
The practice provides no treatment, therapy, aftercare, recovery coaching, referrals to affiliated programs, or ongoing clinical relationship. There is no organizational benefit to any particular finding or conclusion, and no financial interest in the outcome beyond producing an accurate document. That condition is what allows the evaluation to serve as an independent reference rather than a document produced under ambiguous incentives.
No public client list, no published case studies, no reference to engagements in marketing, no solicited testimonials. Records, scheduling, and correspondence are handled under standard professional confidentiality. The practice operates a single-evaluator model, so there is no wider staff with incidental access to clinical records.
Evaluations are conducted entirely by secure telehealth across Minnesota, with no in-person attendance at a clinical facility at any stage. This has been the practice’s delivery model since founding, chosen for clinical and operational reasons rather than adopted as a pandemic-era accommodation.
People come to this work deliberately, usually with counsel or a trusted advisor, and usually with a specific question or an approaching decision in mind rather than as a first step toward treatment. The practice’s role is to produce a structured clinical document you can use as you see fit: to inform your own thinking, to share with counsel or advisors, to provide to a third party with your express authorization, or simply to hold as a clinical reference.
Confidentiality here is structural rather than asserted. Private-pay means no insurance record. A single evaluator means no incidental staff access. Assessment-only means no continuing relationship generating further records over time. A discreet posture means no marketing reference, no client list, and no disclosure through case studies. Where a report may go to a third party, the scope of that authorization is documented in writing, and you control what is shared and with whom.
The evaluation itself meets the practice’s full methodological standard. The structured interview, the history review, the ASAM analysis, and the report are conducted with the same rigor applied to forensic and licensure work. The deliverable is a written clinical report that keeps documented evidence, analysis, and evaluator conclusions clearly separate, formatted for whatever context you determine.
Estate planning counsel, trust officers, family office staff, and family enterprise advisors occasionally meet client situations where an independent substance use evaluation is appropriate. The practice is structured to serve those engagements without complicating your relationship with the client or the integrity of the documentation.
Trust instruments increasingly carry conditional distribution provisions, trustee discretion language, and behavioral compliance triggers that require structured clinical assessment to administer. A trustee facing a distribution decision tied to documented sobriety or behavioral stability needs documentation that supports the decision and holds up under later beneficiary review. The practice provides that under conditions appropriate for fiduciary use: independent of treatment interests, independent of beneficiary and grantor preferences, and methodologically rigorous enough to support the administration record.
Attorneys drafting instruments that contemplate substance use, whether conditional distributions, supplemental needs provisions, or contingent beneficiary structures, sometimes have client questions that benefit from a structured clinical reference before the language is final. The practice does not draft or interpret legal instruments and does not produce documentation meant to substitute for legal analysis. What it documents is the clinical picture the instrument language will operate against.
Where administration becomes disputed, where capacity questions arise alongside substance use, or where a beneficiary challenge raises clinical questions, an independent evaluation may inform what is available to counsel. The practice produces clinical documentation only. It does not provide expert witness testimony, deposition appearance, or trial work. Where litigation may follow, weigh that limitation at the engagement stage.
Individuals anticipating a regulatory, professional, or reputational disclosure sometimes seek an independent evaluation to inform their thinking before formal proceedings begin. Counsel and advisors managing those situations may find the practice a structurally appropriate evaluator. The resulting evaluation is held by the individual and is not transmitted without explicit authorization.
Family enterprise structures and family office governance occasionally surface substance use concerns about principals, heirs, or family members in positions that affect enterprise or asset decisions. The practice can serve as an independent evaluator in those contexts, working alongside family office leadership, family counsel, or enterprise consultants as the engagement requires.
The practice runs three assessment levels, calibrated to complexity. Confidential evaluations are typically conducted at one of the deeper two, since the contexts described above generally exceed what the standard assessment is designed to address. The level is set at intake, based on the posture of the matter, prior assessment history, the clinical question, and the intended use of the report. The three levels are set out on the How it works page.
The deeper two levels incorporate the Arlucent Seventh Dimension™, a structured analysis of whether an individual’s stated commitments and their documented behavior align over time. It is particularly relevant in fiduciary, governance, and pre-disclosure contexts, where that alignment is often the operative question, and where standard ASAM analysis addresses it only partially.
Reports keep documented evidence, structured analysis, and evaluator conclusions clearly separate. Diagnoses are documented with severity and evidentiary basis. A level-of-care opinion, where included, is framed as clinical opinion and explicitly distinguished from placement authorization or treatment mandate. The report takes no advocacy posture and reaches no legal, fiduciary, or governance determinations; those are reserved to the operative authority, whether the trustee, counsel, family office leadership, the individual, or the regulating body.
See the three levels on How it works → / Learn about the Arlucent Seventh Dimension™ →
An engagement may be initiated by the individual directly, or through counsel or an advisor acting with the individual’s authorization. Intake is brief and confidential. Eligible engagements are then confirmed in writing, with scope, level, documentation requirements, scheduling, and fees settled before anything is scheduled. The evaluation is conducted by secure telehealth, and the written report is delivered to the individual or to the authorized recipient identified at engagement.
Fees are private-pay and confirmed in writing at the engagement stage. The practice does not publish fee schedules and does not discuss fees outside an engagement-specific intake. Expedited scheduling, broader documentation scope, or multi-stakeholder coordination can be accommodated where capacity permits, and any such arrangement is confirmed at intake.
Evaluations are conducted by Rafael Lewis, M.A., LADC, founder of Arlucent Assessments, a Licensed Alcohol and Drug Counselor in Minnesota, a doctoral student in counseling psychology at Saint Mary’s University of Minnesota, and the developer of the Arlucent Seventh Dimension™. His clinical and administrative experience includes leadership roles in licensed substance use treatment settings, giving him direct working knowledge of the methods, regulatory standards, and structural considerations that high-stakes independent evaluation work demands.
Further information on credentialing, professional accountability, and scope of practice is on the About page.
An engagement begins with intake review. You may complete the questionnaire directly, or counsel and advisors may initiate the inquiry for a client with the client’s authorization. Intake is confidential and is used to confirm scope, the appropriate level, and the structure of the engagement. Scheduling, documentation, and fees are confirmed in writing afterward.
Engagements are confirmed once payment is received. Inquiries from counsel and advisors are welcome.
Arlucent Assessments · Independent Evaluation
Minnesota
© 2026 Arlucent Assessments™. All rights reserved. A division of Arlucent.
Arlucent Assessments provides independent clinical evaluation services only and does not provide therapy, treatment, clinical care, advocacy, referrals, or ongoing professional services.
Inquiries are handled in accordance with applicable confidentiality and privacy standards.